Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by Barclays PLC

Barclays PLC grew its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 70.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 155,179 shares of the biotechnology company's stock after buying an additional 64,101 shares during the period. Barclays PLC owned 0.18% of Anavex Life Sciences worth $882,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Atria Investments Inc acquired a new position in Anavex Life Sciences during the third quarter valued at $76,000. BNP Paribas Financial Markets increased its stake in shares of Anavex Life Sciences by 97.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company's stock valued at $86,000 after purchasing an additional 7,421 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Anavex Life Sciences by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company's stock valued at $93,000 after purchasing an additional 6,366 shares during the period. Erste Asset Management GmbH purchased a new position in shares of Anavex Life Sciences during the 3rd quarter valued at approximately $102,000. Finally, Balentine LLC purchased a new stake in Anavex Life Sciences in the 3rd quarter worth $115,000. 31.55% of the stock is currently owned by institutional investors and hedge funds.

Anavex Life Sciences Price Performance

Shares of AVXL traded down $0.30 during midday trading on Tuesday, reaching $10.74. The stock had a trading volume of 2,703,316 shares, compared to its average volume of 1,289,191. The company has a market cap of $910.92 million, a price-to-earnings ratio of -21.48 and a beta of 0.73. The company's fifty day simple moving average is $8.40 and its two-hundred day simple moving average is $6.51. Anavex Life Sciences Corp. has a 1-year low of $3.25 and a 1-year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. On average, sell-side analysts forecast that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current year.

Analyst Ratings Changes

AVXL has been the topic of a number of research reports. D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research note on Monday, December 23rd. HC Wainwright boosted their target price on Anavex Life Sciences from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, December 26th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.